Format

Send to

Choose Destination
Trends Immunol. 2003 Oct;24(10):524-7.

BTLA: a new inhibitory receptor with a B7-like ligand.

Author information

1
Inflammation, Wyeth Research, 200 Cambridge Park Drive, Cambridge, MA 02140, USA. bcarreno@wyeth.com

Abstract

The B and T lymphocyte attenuator, BTLA, is a recently discovered Ig superfamily member. BTLA engagement results in downregulation of T-cell activation, and mice deficient in BTLA show increased incidence and severity of autoimmune disorders. A novel B7 family member, B7x (B7S1, B7-H4), has been proposed as the ligand for BTLA. A B7x-Ig fusion protein inhibits T-cell activation and interleukin-2 (IL-2) production. Thus, cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1) and BTLA comprise an expanding set of inhibitory receptors expressed on lymphocytes.

PMID:
14552835
DOI:
10.1016/j.it.2003.08.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center